Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation

Stopped early · Phase 2

Conditions studied: Hematologic Malignancies

In brief

Allogeneic stem cell transplantation is a potentially curative treatment for patients with many hematologic malignancies (e.g. leukemia, lymphoma, and myeloma with high risk of relapse). This process requires a suitable donor. The best case scenario involves an Human Leukocyte Antigen (HLA) matched sibling donor. However, this type of donor is not always available. Donor registries can provide another source for matched unrelated donors, but this may take valuable time delaying treatment for the transplant recipient. Donor availability remains a significant barrier to the use of allogeneic (from a donor) stem cell transplant. This issue disproportionately affects patients of minority backgrounds. Novel strategies to improve outcomes using alternative donors are desperately needed. Haploidentical transplants are an alternative which provides a readily available donor in the form of a partially HLA matched family member. This provides for more potential donors and the donors can be selected based on other factors that can play a role in transplant success (e.g. age, gender, KIR alloreactivity). Recent advances in transplant techniques have greatly improved success rates with haploidentical transplants although disease relapse has remained as issue. This trial aims to provide an alternative transplant option for patients with hematologic malignancies who require bone marrow transplantation but lack an HLA identical donor. The investigational component of this study is the combination of the Fludarabine/ Busulfan/ Total Body Irradiation conditioning regimen and the HLA Haploidentical Transplant with post-transplant Cyclophosphamide.

Key facts

Study ID: NCT01749293
Run by: University of Illinois at Chicago
People needed: 3
Starts: 2012-08-30
Expected to finish: 2014-05-15
Last updated by the study team: 2020-02-25

Who can join

Age: 10 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

First-degree related donor or half-sibling who is at minimum HLA haploidentical
Lack of fully matched donor (related or unrelated). Patients with a matched unrelated donor may only be enrolled if they require an urgent transplant. Urgency of transplant will judged by PI and co-investigators.
Eligible diagnoses are listed below:
Low-grade non-Hodgkin's lymphoma or plasma cell neoplasm that has progressed during multiagent therapy including follicular lymphoma, Marginal zone (or MALT) lymphoma, lymphoplasmacytic lymphoma / Waldenstrom's macroglobulinemia, Hairy cell leukemia, Small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL), Prolymphocytic leukemia, Multiple myeloma and Plasma cell leukemia
Poor-risk SLL or CLL
Aggressive lymphoma that has failed at least one prior regimen of multiagent chemotherapy, and patient is either ineligible for autologous BMT or autologous BMT is not recommended including Hodgkin lymphoma, high grade Follicular lymphoma, Mantle cell lymphoma, Diffuse large B-cell lymphoma, Burkitt's lymphoma/leukemia, Anaplastic large cell lymphoma, Plasmablastic lymphoma, Peripheral T-cell lymphoma
Relapsed or refractory acute leukemias.
Poor-risk acute leukemia in first remission:
i. Acute myeloid leukemia (AML) with at least one of the following:
AML arising from myelodysplastic syndrome (MDS) or a myeloproliferative disorder
Presence of FLT3 internal tandem duplications
Poor-risk cytogenetics
ii. Acute lymphoblastic leukemia and/or lymphoma (ALL) with at least one of the following:
Poor risk cytogenetics
Primary refractory disease
iii. Biphenotypic leukemia
f. MDS with at least one of the following poor-risk features: i. Poor-risk cytogenetics ii. Int-2 or high IPSS score iii. Treatment-related MDS iv. MDS diagnosed before age 21 years v. Progression on or lack of response to standard hypomethylator therapy vi. Life-threatening cytopenias
g. Imatinib-refractory chronic myelogenous leukemia (CML) in accelerated or chronic phase
h. Philadelphia chromosome negative myeloproliferative neoplasm
i. Chronic myelomonocytic leukemia
Adequate end-organ function as measured by:
Left ventricular ejection fraction ≥ 35%
Bilirubin ≤ 3.0 mg/dL and ALT and AST < 5 x ULN
FEV1 and FVC > 40% of predicted
Karnofsky score > 60

Where it is running

University of Illinois Cancer Center — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.